| Literature DB >> 33898103 |
Javid Sadri Nahand1, Layla Shojaie2, Seyed Amirreza Akhlagh3, Mohammad Saeid Ebrahimi4, Hamid Reza Mirzaei5, Hossein Bannazadeh Baghi6, Maryam Mahjoubin-Tehran7, Nima Rezaei5,8,9, Michael R Hamblin10,11, Vida Tajiknia12, Neda Rahimian13, Hamed Mirzaei14.
Abstract
Viral infections lead to the death of more than a million people each year around the world, both directly and indirectly. Viruses interfere with many cell functions, particularly critical pathways for cell death, by affecting various intracellular mediators. MicroRNAs (miRNAs) are a major example of these mediators because they are involved in many (if not most) cellular mechanisms. Virus-regulated miRNAs have been implicated in three cell death pathways, namely, apoptosis, autophagy, and anoikis. Several molecules (e.g., BECN1 and B cell lymphoma 2 [BCL2] family members) are involved in both apoptosis and autophagy, while activation of anoikis leads to cell death similar to apoptosis. These mechanistic similarities suggest that common regulators, including some miRNAs (e.g., miR-21 and miR-192), are involved in different cell death pathways. Because the balance between cell proliferation and cell death is pivotal to the homeostasis of the human body, miRNAs that regulate cell death pathways have drawn much attention from researchers. miR-21 is regulated by several viruses and can affect both apoptosis and anoikis via modulating various targets, such as PDCD4, PTEN, interleukin (IL)-12, Maspin, and Fas-L. miR-34 can be downregulated by viral infection and has different effects on apoptosis, depending on the type of virus and/or host cell. The present review summarizes the existing knowledge on virus-regulated miRNAs involved in the modulation of cell death pathways. Understanding the mechanisms for virus-mediated regulation of cell death pathways could provide valuable information to improve the diagnosis and treatment of many viral diseases.Entities:
Keywords: anoikis; apoptosis; autophagy; cell death; microRNAs; viruses
Year: 2021 PMID: 33898103 PMCID: PMC8056183 DOI: 10.1016/j.omtn.2021.03.011
Source DB: PubMed Journal: Mol Ther Nucleic Acids ISSN: 2162-2531 Impact factor: 8.886
Figure 1Indirect effects of viruses on the apoptotic pathway through deregulation of cellular miRNAs
miR-2861 increased the apoptosis of cervical cancer cells through the PI3K/AKT pathway by targeting EGFR. HPV16 E6 is able to downregulate the miR-2861 expression level and can contribute to tumor development. Moreover, HPV-16 E6/DNMT1 can suppress miR-23b expression and contribute to apoptosis resistance through the blocking inhibitory effect of miR-23b on c-MET. EBV-LMP-1 protects B cell lymphoma from rituximab-induced apoptosis via miR-155-mediated Akt activation and upregulation of Mcl-1. LMP1 can increase miR-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced apoptosis by suppressing PDCD4 and Fas-L. HBV infection can also lead to the induction of apoptosis via the upregulation of miR-194-5p expression in vitro. miR-194-5p-mediated suppression of cFLIP expression strongly sensitizes HepG2 cells to undergo apoptosis in response to a physiological stimulus. The transforming growth factor β (TGF-β) signaling pathway, a major intercellular signaling pathway in mammalian cells, plays a key role in regulating many cellular processes, such as cell proliferation, differentiation, and apoptosis. TGF-β signaling is known to depend on the formation of Smad2/3-Smad4 transcription regulatory complexes. EBV LMP-2A inhibits the expression level of Smad2 through regulating miR-155-5p in gastric cancer cell lines and inhibits apoptosis. Rotavirus infection leads to up-regulation of TGF-β, which may lead to early apoptosis thus preventing virus progression. However, rotavirus counteracts this by upregulation of miR-142-5p. Rotavirus NSP5 upregulates miR-142-5p, which targets several components of the TGF-β signaling pathway. The mitochondrial pathway of apoptosis is dependent on the BCL-2 (B cell CLL/lymphoma 2) family of proteins for the efficient release of pro-apoptotic factors from the mitochondrial intermembrane space. The BCL-2 family is divided into three groups based on their primary function: (1) anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1/A1); (2) pro-apoptotic pore formers (BAX, BAK, BOK); and (3) pro-apoptotic BH3-only proteins (e.g., BAD, BID, BIK, BIM). miR-503 and miR-15a/16 can target the 3′ UTR of Bcl-2 and inhibit hepatocellular carcinoma cell growth. However, HCV NS5A and HBV mRNA decrease miR-503 and miR-15a/16 expression, respectively, and increase Bcl-2 expression, which leads to a decrease in apoptosis.
Figure 2Indirect effects of viruses on the autophagy pathway through deregulation of cellular miRNAs
Autophagy involves the spatially and temporarily coordinated activation of multiple molecular components, including the ULK1 (UNC-51-like kinase 1), FIP200 (FAK family kinase-interacting protein of 200 kDa), and ATG13–ATG101 complex, which is functionally coupled to the negative autophagy regulator, mTOR complex 1, and initiates autophagy. The lipid kinase vacuolar protein sorting 34 (VPS34)-Beclin-1 complex is usually inactivated by anti-apoptotic proteins from the BCL-2 family, but when it is activated it drives the nucleation of the isolation membrane. The AMP-activated protein kinase (AMPK)-mammalian target of rapamycin (mTOR) signaling pathway is well known to be associated with autophagy, and AMPK can promote the initiation of autophagy. Activation of AMPK can result in the inhibition of mTOR, which is commonly activated in malignant cells. miR-106a is upregulated by the HPV-16 E7 oncogene and stimulates cell proliferation and suppresses autophagy by targeting LKB1 via the AMPK-mTOR pathway in HPV-16-associated cervical cancer. Autophagy contributes to HBV replication, as confirmed by observations that autophagy inhibition strongly impaired replication of HBV in liver cells. The expression level of miR-155 was upregulated in HBV-infected cells, and miR-155 reinforced HBV replication by affecting the SOCS1/Akt/mTOR-autophagy axis. HBV also promoted autophagy through the miR-192-3p-XIAP axis, which is important for HBV replication in vitro and in vivo. Beclin-1 is a key autophagy-promoting gene in the early phase of autophagosome formation. It has been shown that EV71 infection induced autophagosome formation through the reduction of cellular miR-30a, which led to the inhibition of Beclin-1.
Figure 3Comparison of apoptosis and anoikis
The lack of ECM contact or the engagement with inappropriate ECM leads to the activation of anoikis either by death receptors (extrinsic pathway) or mitochondria (intrinsic pathway).
Figure 4Mechanism of the autophagy pathway
A series of stepwise processes, i.e., initiation, nucleation, elongation, maturation, and fusion with lysosomes, are involved in autophagy. Autophagy is induced at a basal level under normal conditions and is further stimulated by stress, for example, by nutrient deprivation
Virus-regulated miRNAs known to play roles in modulating cell death pathways
| Virus | Viral protein | miRNA | Expression of miRNA | Target of miRNA | Inhibition/ induction of cell death | Disease | Sample type | Ref. |
|---|---|---|---|---|---|---|---|---|
| HPV 16 | E7 | miR-27b | up | polo-like kinase2 | inhibition of apoptosis | cervical | ||
| HPV 16 | E7 | miR-21 | up | – | inhibition of apoptosis | cervical | ||
| HPV 16 and 18 | E6 | miR-34a | down | – | inhibition of apoptosis | cervical | human (cervical cancer tissue samples) | |
| HPV 16 | E6 | miR-2861 | down | CCND1, EGFR, AKT2 | inhibition of apoptosis | cervical | human (n = 57 cervical cancer tissue samples) | |
| HPV 16 | E6 | miR-23b | down | c-MET | inhibition of apoptosis | cervical cancer | ||
| HPV 16 | E5 | miR-196a | down | HoxB8 | inhibition of apoptosis | cervical | ||
| HPV 16 and 18 | E6, E7 | miR-18a | up | STK4 | inhibition of apoptosis | cervical | human (cervical cancer tissue samples) | |
| EBV | EBNA2 | miR-34a | down | PD-L1 | inhibition of apoptosis | Burkitt’s lymphoma | ||
| EBV | LMP2A | miR-155-5p | up | Smad2 | inhibition of apoptosis | gastric cancer | ||
| EBV | LMP1 | miR-21 | up | PDCD4, Fas-L | inhibition of apoptosis | nasopharyngeal carcinoma | ||
| EBV | LMP1 | miR-155 | up | UBQLN1 | inhibition of apoptosis | nasopharyngeal carcinoma | human (n = 8 radio-resistant tissue samples of NPC) | |
| EBV | – | miR-155 | up | – | inhibition of apoptosis | B cell lymphoma | ||
| EBV | LMP1 | miR-155 | up | PTEN | inhibition of apoptosis | B cell lymphoma | ||
| EBV | EBNA1 | miR34a | down | – | inhibition of apoptosis | gastric cancer | ||
| EBV | – | miR-194 | down | IL-10 | inhibition of apoptosis | PTLD | human (n = 6 PBMC samples of PTLD) | |
| HBV | HBx | miR-21 | up | IL-12 | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-21 | up | PDCD4, | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-181a | up | PTEN | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-192-5p | up | BIM | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-331-3p | up | ING5 | inhibition of apoptosis | HCC | human (HCC tissue samples) | |
| HBV | HBx | miR-602 | up | RASSF1A | inhibition of apoptosis | HCC | human (n = 21 HCC tissue samples) | |
| HBV | – | miR-15a | down | Smad7 | inhibition of apoptosis | HCC | human (n = 40 HCC tissue samples) | |
| HBV | – | miR-30e-5p | down | MAP4K4 | inhibition of apoptosis | HCC | human (n = 55 HCC tissue samples) | |
| HBV | – | miR-15a/16 Cluster | down | Bcl-2 | inhibition of apoptosis | HCC | human (n = 40 HCC tissue samples) | |
| HBV | HBx | miR-1236 | down | alpha-fetoprotein (AFP) | inhibition of apoptosis | HCC | human (n = 97 tissue samples of HCC) | |
| HBV | HBx | miR-1270 | down | alpha-fetoprotein (AFP) | inhibition of apoptosis | HCC | human (n = 97 HCC tissue samples) | |
| HBV | – | miR-101-3p | down | Rab5a | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-15a and 15b | down | CCND1 | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-16 | down | CCND1 | inhibition of apoptosis | HCC | ||
| HBV | HBx | let-7 | down | – | inhibition of apoptosis | HCC | human (n = 19 HCC tissue samples) | |
| HBV | HBx | miR-193b | down | – | inhibition of apoptosis | HCC | human (HCC tissue samples) | |
| HBV | HBx | miR-548p | down | HBXIP | inhibition of apoptosis | HCC | human (n = 21 HCC tissue samples) | |
| HBV | HBx | miR-375 | down | AEG-1 | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-136 | down | AEG-1 | inhibition of apoptosis | HCC | ||
| HBV | HBx | miR-192 | down | – | inhibition of apoptosis | HCC | ||
| HBV | HBx | miRNA-145 | down | CUL5 | inhibition of apoptosis | HCC | human (n = 25 HCC tissue samples) | |
| HBV | HBc, | miR-328-3p | up | FOXO4 | inhibition of apoptosis | – | ||
| HBV | – | miR-98-5p | up | NF-κB | induction of apoptosis | HCC | human (n = 30 HCC tissue samples) | |
| HCV | – | miR-155 | up | APC | inhibition of apoptosis | HCC | human (n = 10 HCC tissue samples) | |
| HCV | core | miR-345 | up | p21Waf1/Ci1 | inhibition of apoptosis | – | ||
| HCV | core | miR-93 | up | – | inhibition of apoptosis | – | ||
| HCV | core | miR-30c | down | – | inhibition of apoptosis | HCC | human (n = 152 HCC tissue samples) | |
| HCV | core | miR-203a | down | – | inhibition of apoptosis | HCC | human (n = 152 HCC tissue samples) | |
| HCV | NS5A | miR-503 | down | Bcl-2 | inhibition of apoptosis | – | ||
| HCV | – | miR-193b | down | Mcl-1 | inhibition of apoptosis | HCC | ||
| HCV | – | miR-181c | down | ATM | inhibition of apoptosis | – | human (n = 8 tissue samples of chronically HCV-infected) | |
| HTLV-1 | Tax | miR-155 | up | – | inhibition of apoptosis | ATLL | ||
| HTLV-1 | Tax | miR-130b | up | TP53INP1 | inhibition of apoptosis | ATLL | human (PBMC samples of ATLL) | |
| HTLV-1 | – | miR-93 | up | TP53INP1 | inhibition of apoptosis | ATLL | human (PBMC samples of ATLL) | |
| Influenza A | – | miR-29c | up | BCL2L2 | induction of apoptosis | influenza | ||
| GaHV-2 | Meq | miR-21 | up | PDCD4 | inhibition of apoptosis | Marek’s disease, lymphoma | ||
| Rotavirus | NSP5 | miR-142-5p | up | SMAD3, TGFβR2 | inhibition of apoptosis | – | ||
| HSV-1 | – | miR-23a | up | IRF1 | inhibition of apoptosis | – | ||
| HBV | HBx | miR-194-5p | up | cFLIP, SODD | induction of apoptosis | HCC | ||
| HCV | – | miR-200c | up | FAP1 | induction of apoptosis | hepatic fibrosis | human (n = 10 tissue samples of HCV fibrosis) | |
| Influenza A (H1N1) | – | miR-34a | down | Bax | induction of apoptosis | influenza | human (n = 10 influenza serum samples) | |
| Enterovirus 71 | – | let-7b | up | CCND1 | induction of apoptosis | – | ||
| West Nile virus | – | Hs_154 | up | ECOP, CTCF | induction of apoptosis | – | ||
| RSV | NS1 | miR-24 | down | – | induction of apoptosis | – | ||
| HBV | HBx | miR-192-3p | down | XIAP | induction of autophagy | hepatitis B | human (serum samples of hepatitis B) | |
| HBV | HBsAg | miR-155 | up | SOCS1/Akt/mTOR | induction of autophagy | – | ||
| Enterovirus 71 | – | miR-30a | down | Beclin-1 | induction of autophagy | – | ||
| HBV | – | miR-224 | up | Smad4 | inhibition of autophagy | HCC | human (HCC tissue samples) | |
| HPV 16 | E7 | miR-106a | up | LKB1 | inhibition of autophagy | cervical cancer | human (n = 91 cervical cancer tissue samples) | |
| HBV | HBx | miR-7 | up | maspin | inhibition of anoikis | HCC | human (n = 69 HCC tissue samples) | |
| HBV | HBx | miR-107 | up | maspin | inhibition of anoikis | HCC | human (n = 69 HCC tissue samples) | |
| HBV | HBx | miR-21 | up | maspin | inhibition of anoikis | HCC | human (n = 69 HCC tissue samples) |
PBMC, peripheral blood mononuclear cell.